EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieOpen Access · CC BY 4.0

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review

Simone Lisa Böll iD, Seyed Morteza Seyed Jafari, Curdin Conrad iD, Christoph Schlapbach

International Journal of Molecular Sciences · 30.10.2025 · 26 (21) · 10592

DOI: 10.3390/ijms262110592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.10.2025. Verfasst von Simone Lisa Böll und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Pyrazoles, Janus Kinase Inhibitors, Skin Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus Kinase Inhibitors (JAKi) represent a novel class of drugs for the treatment of chronic inflammatory skin diseases. Topical JAKi (t-JAKi) offer targeted therapy at potentially reduced systemic side effects and improved long-term safety compared to systemic JAKi (s-JAKi). This narrative review assesses the pharmacokinetics and safety profile of currently available t-JAKi, ruxolitinib and delgocitinib, with a comparative analysis to s-JAKi. Pharmacokinetic data show that topical ruxolitinib achieves effective dermal concentrations, with minimal systemic exposure. Clinical trials consistently report low rates of adverse events, primarily application-site reactions, while systemic events such as upper respiratory tract infections occur at rates comparable to placebo. Data on delgocitinib similarly indicate negligible systemic absorption and a favorable safety profile. Taken together, these findings suggest that t-JAKi may represent safer alternatives to s-JAKi for selected patients with localized inflammatory skin diseases, particularly those with comorbidities or heightened systemic risk. Long-term studies and real-world evidence are needed to confirm sustained safety and guide their optimal integration into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesJanus Kinase InhibitorsSkin DiseasesHumansNitrilesPyrimidinesAdministration, Topical

Stichwörter der Autor:innen

Janus kinase inhibitorsatopic dermatitischronic inflammatory skin diseasesdelgocitinibruxolitinibsafety profilesystemic therapytopical therapy

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department of Dermatology and Venereology, University Hospital of Lausanne, 1005 Lausanne, Switzerland.
  • Department of Dermatology and Venereology, University of Freiburg, 79085 Freiburg im Breisgau, Germany.

ORCID-Profile: Simone Lisa Böll, Curdin Conrad

Zitieren

APA

Böll, S. L., Seyed Jafari, S. M., Conrad, C., & Schlapbach, C. (2025). Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. International Journal of Molecular Sciences, 26(21), 10592. https://doi.org/10.3390/ijms262110592

Vancouver

Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C. Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. International Journal of Molecular Sciences. 2025;26(21):10592. doi:10.3390/ijms262110592

BibTeX
@article{Bll2025,
  author = {Böll, Simone Lisa and Seyed Jafari, Seyed Morteza and Conrad, Curdin and Schlapbach, Christoph},
  title = {Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {21},
  pages = {10592},
  doi = {10.3390/ijms262110592}
}
Kostenlos starten →